166. Pseudoxanthoma elasticum Clinical trials / Disease details


Clinical trials : 16 Drugs : 27 - (DrugBank : 5) / Drug target genes : 5 - Drug target pathways : 28

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02537054
(ClinicalTrials.gov)
September 201521/8/2015Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)Intravitreal Aflibercept (Eylea) for Therapy of Choroidal Neovascularization (CNV) and Fibrovascular Proliferation (FVP) in Patients With Pseudoxanthoma Elasticum (PXE)Pseudoxanthoma ElasticumDrug: AfliberceptUniversity Hospital, BonnNULLCompleted18 Years65 YearsAll15Phase 2Germany
2EUCTR2014-005263-33-DE
(EUCTR)
29/04/201526/02/2015Intravitreal Aflibercept (Eylea®) for therapy of choroidal neovascularization and fibrovascular proliferation in patients with Pseudoxanthoma elasticumIntravitreal Aflibercept (Eylea®) for therapy of choroidal neovascularization and fibrovascular proliferation in patients with Pseudoxanthoma elasticum - EyNeP Choroidal neovascularizations and fibrovascular proliferations in patients with Pseudoxanthoma elasticum
MedDRA version: 20.0;Level: PT;Classification code 10037150;Term: Pseudoxanthoma elasticum;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Trade Name: EyleaMedizinische Fakultät der Universität BonnNULLNot RecruitingFemale: yes
Male: yes
15Phase 2Germany